{"protocolSection":{"identificationModule":{"nctId":"NCT06470633","orgStudyIdInfo":{"id":"NJMU- BC03"},"organization":{"fullName":"The First Affiliated Hospital with Nanjing Medical University","class":"OTHER"},"briefTitle":"To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer","officialTitle":"To Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy Neoadjuvant Therapy in Early or Local Advanced Breast Cancer After Induction Treatment of High-intensity Focused Ultrasound and Adebrelimab"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-08-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-06-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-18","studyFirstSubmitQcDate":"2024-06-18","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-18","lastUpdatePostDateStruct":{"date":"2024-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Wenbin Zhou","investigatorTitle":"Professor","investigatorAffiliation":"The First Affiliated Hospital with Nanjing Medical University"},"leadSponsor":{"name":"The First Affiliated Hospital with Nanjing Medical University","class":"OTHER"},"collaborators":[{"name":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To explore the efficacy and safety of adebrelimab combined with chemotherapy (epirubicin + cyclophosphamide →docetaxel) neoadjuvant therapy early HR+/HER2- breast cancer with high risk factors after the induction treatment of HIFU and adebrelimab."},"conditionsModule":{"conditions":["Breast Cancer","HR+/HER2- Breast Cancer"],"keywords":["HR+/HER2- early breast cancer","HIFU","Immunotherapy","Neoadjuvant therapy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":29,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"HIFU+Adebrelimab+Chemotherapy","type":"EXPERIMENTAL","description":"Induction phase: HIFU+Adebrelimab Neoadjuvant Therapy phase: Adebrelimab+ EC-T(Epirubicin + Cyclophosphamide → Docetaxel","interventionNames":["Drug: Adebrelimab","Procedure: High Intensity Focused Ultrasoun（HIFU）","Drug: Cyclophosphamide","Drug: Epirubicin","Drug: Docetaxel"]}],"interventions":[{"type":"DRUG","name":"Adebrelimab","description":"Adebrelimab 1200mg iv q3w","armGroupLabels":["HIFU+Adebrelimab+Chemotherapy"],"otherNames":["PD-Li"]},{"type":"PROCEDURE","name":"High Intensity Focused Ultrasoun（HIFU）","description":"HIFU treatment at lesion site","armGroupLabels":["HIFU+Adebrelimab+Chemotherapy"]},{"type":"DRUG","name":"Cyclophosphamide","description":"600mg/m2 iv q3w","armGroupLabels":["HIFU+Adebrelimab+Chemotherapy"]},{"type":"DRUG","name":"Epirubicin","description":"90mg/m2 iv q3w","armGroupLabels":["HIFU+Adebrelimab+Chemotherapy"]},{"type":"DRUG","name":"Docetaxel","description":"75mg/m2 iv q3w","armGroupLabels":["HIFU+Adebrelimab+Chemotherapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"tpCR","description":"total pathologic complete response rate（lymph node and breast）","timeFrame":"6 months"}],"secondaryOutcomes":[{"measure":"bpCR","description":"breast pathologic complete response rate","timeFrame":"6 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Female patients aged ≥ 18 years who require a negative pregnancy test for premenopausal and perimenopausal patients and promise to take reliable contraceptive measures during treatment;\n2. Histopathologically confirmed breast cancer patients who with hormone receptor- positive, which defined as estrogen receptor (ER) ≥ 1%, and/ or progesterone receptor (PR) ≥ 1%, and HER-2 (0 or +), or ++,but FISH is no amplification;\n3. Tumor size ≥ 3cm, and histological grade is 3 (poorly differentiated);\n4. Regardless of lymph node status, but without distant metastasis;\n5. According to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, they have at least one evaluable target lesion;\n6. ECOG PS score: 0 - 1;\n7. New York Heart Association (NYHA) functional class I;\n8. Electrocardiogram without myocardial ischemia, echocardiography LVEF \\> 55%, cardiac markers: cardiac troponin I (cTnI) and brain natriuretic peptide (BNP) test values within the normal range;\n9. Normal major organ function, Meet the following criteria:\n\nWBC ≥ 4.0 × 10 9/L,Neutrophil count (ANC) ≥ 1.5 × 10 9/L; platelet ≥ 100 × 10 9/L; hemoglobin ≥ 10 g/dL; serum creatinine ≤ 1.5 × upper limit of normal (ULN); aspartate aminotransferase (AST) ≤ 2.5 × ULN; alanine aminotransferase (ALT) ≤ 2.5 × ULN; total bilirubin ≤ 1.5 × ULN; serum creatinine ≤ 1.5 × ULN; 9.The subject is able to understand the study procedures, voluntarily join the study, sign the informed consent form, have good compliance, and cooperate with the follow-up.\n\nExclusion Criteria:\n\n1. Patients during pregnancy and lactation, women of childbearing age who refuse to take effective contraceptive measures during the study period; Patients with peripheral nervous system disorders caused by diseases or those with a history of significant mental disorders and central nervous system disorders;\n2. Serious or uncontrolled infections that may affect the evaluation of study treatment or study results, including but not limited to: active hepatitis virus infection, human immunodeficiency virus (HIV) antibody positive, lung infection, etc.;\n3. Known allergy to the active ingredients or other components of the study drug or surgical contraindications;\n4. In addition to cured basal cell carcinoma of the skin and cured cervical carcinoma in situ, other cancers are disease-free for less than 5 years;\n5. Severe liver disease (such as cirrhosis, etc.), kidney disease, respiratory disease or uncontrolled diabetes, active gastrointestinal ulcers and other need treatment;\n6. Need to receive other anti-tumor therapy (except ovarian function inhibitors) during neoadjuvant therapy as judged by the investigator;\n7. Patients who are participating in other clinical trials within one month;\n8. Patients with severe heart disease or discomfort, Expected intolerance to chemotherapy,Including, but not limited to: a. fatal arrhythmia or higher grade atrioventricular block (second-degree type 2 \\[Mobitz 2\\] atrioventricular block or third-degree atrioventricular block); b. unstable angina pectoris; c. clinically significant valvular heart disease; d. transmural myocardial infarction on electrocardiogram; e. uncontrolled hypertension;\n9. Any other conditions that in the opinion of the investigator would make the patient inappropriate for participation in this study.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Wenbin Zhou, Professor","role":"CONTACT","phone":"025-68308162","email":"Zhouwenbin@njmu.edu.cn"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000001943","term":"Breast Neoplasms"}],"ancestors":[{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000001941","term":"Breast Diseases"},{"id":"D000012871","term":"Skin Diseases"}],"browseLeaves":[{"id":"M5220","name":"Breast Neoplasms","asFound":"Breast Cancer","relevance":"HIGH"},{"id":"M5218","name":"Breast Diseases","relevance":"LOW"},{"id":"M15674","name":"Skin Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"D000003520","term":"Cyclophosphamide"},{"id":"D000077143","term":"Docetaxel"},{"id":"D000015251","term":"Epirubicin"}],"ancestors":[{"id":"D000007166","term":"Immunosuppressive Agents"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000018906","term":"Antineoplastic Agents, Alkylating"},{"id":"D000000477","term":"Alkylating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000019653","term":"Myeloablative Agonists"},{"id":"D000050257","term":"Tubulin Modulators"},{"id":"D000050256","term":"Antimitotic Agents"},{"id":"D000050258","term":"Mitosis Modulators"},{"id":"D000000903","term":"Antibiotics, Antineoplastic"},{"id":"D000059005","term":"Topoisomerase II Inhibitors"},{"id":"D000059003","term":"Topoisomerase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M6727","name":"Cyclophosphamide","asFound":"Cycle","relevance":"HIGH"},{"id":"M1668","name":"Docetaxel","asFound":"Physical","relevance":"HIGH"},{"id":"M2853","name":"Immunomodulating Agents","relevance":"LOW"},{"id":"M17954","name":"Epirubicin","asFound":"Syringe","relevance":"HIGH"},{"id":"M10212","name":"Immunosuppressive Agents","relevance":"LOW"},{"id":"M10201","name":"Immunologic Factors","relevance":"LOW"},{"id":"M20604","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M20942","name":"Antineoplastic Agents, Alkylating","relevance":"LOW"},{"id":"M3820","name":"Alkylating Agents","relevance":"LOW"},{"id":"M26197","name":"Tubulin Modulators","relevance":"LOW"},{"id":"M26196","name":"Antimitotic Agents","relevance":"LOW"},{"id":"M4222","name":"Anti-Bacterial Agents","relevance":"LOW"},{"id":"M4224","name":"Antibiotics, Antitubercular","relevance":"LOW"},{"id":"M29348","name":"Topoisomerase Inhibitors","relevance":"LOW"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"}]}},"hasResults":false}